Danaher Corporation vs Eli Lilly & Co.
DHR vs LLY — side-by-side comparison from reported financials. DHR leads 3, LLY leads 8 of 11 comparable metrics.
Danaher Corporation
DHR · Healthcare
$219.81+1.08%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | DHR | LLY |
|---|---|---|
| Price | $219.81 | $1 177.20 |
| Market cap | $155B | $1.05T |
| Revenue (TTM) | $25.1B | $79.7B |
| Revenue growth | -2.7% | +31.7% |
| Net margin | 15.9% | 33.5% |
| Free cash flow | $5.47B | $18.2B |
| Net cash (debt) | ($13.8B) | ($35.2B) |
| 1-year price return | +7.5% | +37.6% |
| P/E | 38.6 | 41.6 |
| P/E vs own history (cheap-side %) | 38% | 88% |
| Dividend yield | 0.62% | 0.52% |
| Return on equity | 8% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 9 of 11 | 11 of 11 |
| Employees | 60,000 | 50,000 |
Full résumé-style profiles: DHR CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.